Glycosmedia

Diabetes News Service

Diabetes News

Category: Medication

Liraglutide in Children and Adolescents with Type 2 Diabetes

In children and adolescents with type 2 diabetes, liraglutide, at a dose of up to 1.8 mg per day (added to metformin, with or without basal insulin), was efficacious in improving glycemic control over 52 weeks. This efficacy came at the cost of an increased frequency of gastrointestinal adverse events (NEJM)

Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction

In a cohort of 12,156 patients with T2DM and high CV risk, metformin use was associated with lower rates of all-cause mortality, including after adjustment for clinical variables and biomarkers, but not lower rates of the composite endpoint of CV death, MI, or ischemic stroke (Circulation)

Class effects of SGLT2 inhibitors on cardiorenal outcomes

Dapagliflozin, empagliflozin, and canagliflozin have internally and externally consistent and biologically plausible class effects on cardiorenal outcomes. Baseline renal filtration function and degree of albuminuria are the most significant indicators of risk for both CV and renal events. Thus, these two factors also anticipate the greatest clinical benefit for SGLT2i (Cardiovascular Diabetology)

Dapagliflozin vs Non‐SGLT‐2i Treatment is Associated with Lower Hospital Care Costs in Type 2 Diabetes Patients Similar to the DECLARE‐TIMI 58 Participants

In a nationwide, real‐world, DECLARE‐like population, dapagliflozin was associated with lower hospital costs compared with oGLD, mainly as a result of reduced rates of CV‐ and T2D‐associated complications (Diabetes, Obesity and Metabolism)

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study

In a large cohort of patients seen in routine clinical practice, risk for severe and nonsevere UTI events among those initiating SGLT-2 inhibitor therapy was similar to that among patients initiating treatment with other second-line antidiabetic medications (Annals of Internal Medicine)

Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy

Adding DAPA + SAXA to insulin-naive patients with poorly controlled type 2 diabetes achieved similar glycemic control, a lower risk of hypoglycemia, and a clinically relevant body weight difference compared with basal INS (Diabetes Care)

The future of new drugs for diabetes management

The future of the newer classes of glucose-lowering drugs, namely dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium/glucose co-transporter-2 (SGLT-2) inhibitors, is being redefined by the large prospective cardiovascular outcome trials (Diabetes Research and Clinical Practice)

Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus

Glycaemic benefits were greater with early versus later dapagliflozin intensification. These results support broader and earlier dapagliflozin use (Diabetes Research and Clinical Practice)

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

The Improving Diabetes Steering Committee seeks to support healthcare professionals (HCPs) in appropriate treatment selection for people with T2DM who are at risk of developing or have established CVD and examines the role of SGLT2i therapy for these people. (Diabetes Therapy)

Do GLP‐1RAs and SGLT‐2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis

While our review suggests that GLP‐1RAs and SGLT‐2is did not significantly reduce cardiovascular risk in black patients with type 2 diabetes, the available data are underpowered to examine this suggestion (Diabetes, Obesity and Metabolism)

GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued

Diabetic ketoacidosis has been reported in patients with type 2 diabetes on a combination of a GLP-1 receptor agonist and insulin who had doses of concomitant insulin rapidly reduced or discontinued. GLP-1 receptor agonists are not substitutes for insulin, and any reduction of insulin should be done in a stepwise manner with careful glucose self-monitoring (Medicines and Healthcare products Regulatory Agency)

SGLT inhibitors: medications that mimic fasting for cardiovascular prevention

This review proposes a unifying hypothesis to explain the reduction in cardiovascular diseases through three different mechanisms of curbing free fatty acid (FFA) excess, all leading to the common mechanism of cellular caloric restriction. If this hypothesis is correct, the excellent results obtained with SGLT‐2 inhibitors could be attributed to their close simulation of fasting  (Diabetes, Obesity and Metabolism)

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices

Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com